IVVD
InvivydBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
Positive clinical data or a meaningful licensing/partnership deal de-risks the pipeline, prompting multiple expansion from a low valuation and material upside versus the anchor.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Need for dilutive financing / insufficient cash runway
Momentum
31
Value
41
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.14 · Bull $1.71 · Bear $0.80
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2025-09-29 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $10.00
Why
Momentum31 · Δ7d -
Value41 · Δ7d +0.0
Sentiment100 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
31
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
100
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 30.9 / Value 41.1 / Sentiment 100.0
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$201.89M
Beta
0.62
Shares Out
294.61M
P/E (TTM) · Derived
-2.2
P/S (TTM)
14.12
P/FCF (TTM) · Derived
-1.95
Rev YoY
+21.6%
EPS YoY
-1.6%
Gross Margin
+89.6%
Op Margin
-124.4%
Net Debt
-$224.2M
Current Ratio
6.47
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology